R&D

Merck enters the Ebola Vaccine Race in NewLink Partnership

Merck enters the Ebola Vaccine Race in NewLink Partnership

Written by on November 25, 2014 in Emerging Markets, R&D with 2 Comments

Merck obtains the rights to NewLink genetics’ experimental Ebola Vaccine, putting pressure on GSK Merck has struck a agreement with NewLink Genetics to licence their investigational Ebola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world. This partnership should allow NewLink to keep pace […]

Continue Reading

Designing the Next Generation of Vaccines

Designing the Next Generation of Vaccines

Written by on November 13, 2014 in R&D with 0 Comments

Sylvie Bertholet, PhD Head In vivo Immunology, Novartis Vaccines & Diagnostics joined us last year at the World Vaccine Congress Europe to present on ‘Designing the Next Generation of Vaccines’ Download this presentation now to find out more about: Designing the Next Generation Vaccines What is a self-amplifying mRNA (replicon)? How does SAM work? A […]

Continue Reading

Therapeutic

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Written by on September 15, 2014 in Prophylactic Vaccines, R&D, Therapeutic Vaccines, Vaccines Live with 1 Comment

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. […]

Continue Reading

Japan May Provide West African Countries With Unapproved Ebola Treatment

Japan May Provide West African Countries With Unapproved Ebola Treatment

Written by on August 27, 2014 in Featured on App, News, Therapeutic Vaccines with 0 Comments

The Japanese government is ready to provide Ebola afflicted countries an experimental drug that has not yet been approved by the WHO On Monday the 27th of August, Japan’s Chief Cabinet Secretary Yoshihide Suga announced that the country is willing to donate a flu drug called Favipiravir to aid the Ebola crisis in west Africa. […]

Continue Reading

Prophylactic

Hybrid Delivery System Boosts DNA Vaccines Potential

Hybrid Delivery System Boosts DNA Vaccines Potential

Written by on December 2, 2014 in Emerging Markets, Featured on App, Flu, Prophylactic Vaccines with 1 Comment

Researchers at the University at Buffalo have developed a hybrid delivery system designed to fight cancer, HIV, flu, and other diseases Scientists from the University at Buffalo have created a novel hybrid system designed to deliver genetic antigens and elicit a strong immune response in patients, something DNA vaccines have so far failed to deliver. […]

Continue Reading

Sanofi’s Dengue Vaccine To Market in 2015

Sanofi’s Dengue Vaccine To Market in 2015

Written by on November 4, 2014 in Emerging Markets, Prophylactic Vaccines with 3 Comments

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the […]

Continue Reading

Flu

Authorities Deem Novartis’ FLUAD Safe

Authorities Deem Novartis’ FLUAD Safe

Written by on December 2, 2014 in Flu, Press Releases with 0 Comments

The Italian AIFA and National institute of Health (ISS) have declared Novartis’ FLUAD as safe Towards the end of November Italian officials prohibited the use of two batches of Novartis’ flu vaccine FLUAD after 13 deaths were reported to have taken place shortly after vaccination (8 within 24 hours). There were concerns from the AIFA […]

Continue Reading

Novartis’ Fluad Investigated After 13 Reported Deaths

Novartis’ Fluad Investigated After 13 Reported Deaths

Written by on December 1, 2014 in Flu with 1 Comment

Two batches of Novartis’ Fluad have been suspended from use whilst Italian authorities investigate 13 deaths that occurred in Italy in November The Italian medicines agency, AIFA, have suspended the use of two batches of Novartis’ influenza vaccine Fluad after the death of 13 adults, 8 of whom were above the age of 80, between […]

Continue Reading

Regulation & Policy

Is the WHO Blaming BigPharma for Ebola?

Is the WHO Blaming BigPharma for Ebola?

Written by on November 5, 2014 in Emerging Markets, News, Regulation and Policy with 1 Comment

No. They’re blaming governments for not investing. WHO Director General, Dr. Margaret Chan, said on Monday that the lack of an Ebola vaccine is due to Ebola historically being confined to poor ‘African nations. At the regional committee for Africa in Benin on Monday, Dr. Chan, Director general of the World Health Organization, said that […]

Continue Reading

Vaccines and Autism: Infographic

Vaccines and Autism: Infographic

Written by on September 23, 2014 in Featured on App, Regulation and Policy with 0 Comments

Source: Healthcare-management-degree.net

Continue Reading

Emerging Markets

Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Written by on November 21, 2014 in Emerging Markets with 2 Comments

Themis Bioscience and the Institut Pasteur announce positive chikungunya vaccine results in phase I using revolutionary measles vector Vienna-based Themis Bioscience, and the Paris based Institut Pasteur announced earlier this week a successful phase I trial of their revolutionary chikungunya vaccine. The phase 1 trial of 42 subjects demonstrated the vaccine to be well tolerated […]

Continue Reading

Reprieve for HIV Vaccines?

Reprieve for HIV Vaccines?

Written by on October 31, 2014 in Emerging Markets with 2 Comments

ALVAC-HIV and AIDSVAX resurected in promising South Africa Trial of the two HIV Vaccines A new trial of the ALVAC-HIV + AIDSVAX HIV vaccine regimen, conducted in South Africa, has demonstrated its safety and a robust immune response amongst 100 healthy adults. This trial, named HVTN 097, comes in the wake of the high-profile disappointment […]

Continue Reading

Supply Chain

Download The Need to Improve: Introducing Innovations in Existing Vaccine Processes

Download The Need to Improve: Introducing Innovations in Existing Vaccine Processes

Written by on November 16, 2014 in Supply Chain with 0 Comments

Ronald Neeleman, Sanofi Pasteur joined us last year at the World Vaccine Congress Europe to present on ‘THE NEED TO IMPROVE: Introducing Innovations in Existing Vaccine Processes’ Download this presentation now to find out more about: Large Companies are Optimized For Stability A turbulent World! Innovation Horizons Simulation of Manufacturing Logistics Anti-counterfeiting Principle of the […]

Continue Reading

The HPV Cancer Vaccine: Two Doses May Be Enough

The HPV Cancer Vaccine: Two Doses May Be Enough

Written by on August 28, 2014 in Featured on App, News, Prophylactic Vaccines, Supply Chain with 0 Comments

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the […]

Continue Reading

Strategy and Partnering

World Vaccine Congress Brochure Available

World Vaccine Congress Brochure Available

Written by on November 26, 2014 in Featured on App, Partnering and Corporate strategy with 0 Comments

The World Vaccine Congress Washington is now in its 15th year, and things look a little different to previous years. ‘So why the change?’ I hear you ask… In my previous role, we produced very focused agendas and ran two-day events specifically on that area. This would be as niche as talking only about foundations […]

Continue Reading

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Written by on September 10, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Two former Merck scientists have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine Two former virologists for Merck have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine. A US district judge from Pennsylvania, Darnell Jones II, has ruled that the pair of whistleblowers have provided […]

Continue Reading

Top
Geolocation